6547.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 01:30):

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally...

Stats
Today's Volume	791 154
Average Volume	1.24M
Market Cap	16.86B
EPS	TWD0 ( 2024-05-03 )
Next earnings date	( TWD0 ) 2024-08-11
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-16.55
ATR14	TWD0.0280 (0.05%)

Volume Correlation

Long: -0.09 (neutral)

Short: -0.58 (weak negative)

Signal:(53.356) Neutral

Medigen Vaccine Biologics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medigen Vaccine Biologics Correlation - Currency/Commodity

-0.55
( weak negative )

-0.52
( weak negative )

0.00
( neutral )

0.62
( weak )

-0.77
( moderate negative )

Medigen Vaccine Biologics Financials

Annual	2023
Revenue:	TWD389.62M
Gross Profit:	TWD221.15M (56.76 %)
EPS:	TWD-3.53

FY	2023
Revenue:	TWD389.62M
Gross Profit:	TWD221.15M (56.76 %)
EPS:	TWD-3.53

FY	2022
Revenue:	TWD365.04M
Gross Profit:	TWD-212.60M (-58.24 %)
EPS:	TWD-4.64

FY	2021
Revenue:	TWD3.28B
Gross Profit:	TWD2.31B (70.25 %)
EPS:	TWD5.09

Financial Reports:

No articles found.

Medigen Vaccine Biologics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.